Navigation Links
Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data
Date:4/17/2008

a Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effe
'/>"/>

SOURCE Arpida
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
5. New knock-out gene model provides molecular clues to breast cancer
6. PreMD Provides Update on 510(k) Application for PREVU(x) POC
7. SIV infection of natural hosts provides new insights into HIV disease complexity
8. Microarray provides 3 genomic guides to breast cancer treatment decisions
9. Access Innovations Provides Support Services for Agis Network
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Physical Therapist Provides Injury Analysis for Fantasy Football
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... cancer is the leading cause of cancer death in ... so many medical professionals encourage women to get mammograms, ... a minority of suspicious mammograms actually leads to a ... worry for women and their familiesnot to mention the ... and biopsies. , Recently, a different type of ...
(Date:9/30/2014)... Dynamic health trends, changing consumer ... the Bread Production industry over the past five ... their consumption of a variety of industry goods ... the market for white loaf bread and other ... introducing more nutritious products to attract health-conscious consumers, ...
(Date:9/30/2014)... Maryland-led research team has been awarded a three-year ... Health (NIH) to develop new imaging technologies and ... of how large networks of neurons in the ... will help researchers identify the precise interactions between ... decision-making and speaking, and alterations in these interactions ...
(Date:9/30/2014)... 2014 The American Diabetes Association ... diabetics curb their sweet tooth, but the most recent ... September, suggests that zero-calorie sweeteners may actually be linked ... , The Weizmann Institute of Science in Israel ... to mice, the mice developed glucose intolerance. They then ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set ... Nashville, Tennessee. RMS welcomes the launch of an entirely ... of a new treatment center for the Lung Institute. ... Institute to Nashville, the hope is to bring awareness ... diagnosed and undiagnosed. With Nashville being a hub for ...
Breaking Medicine News(10 mins):Health News:'Virtual breast' could improve cancer detection 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2
... 2010Announcing the launch of the Liebert Mobile iPhone ... news, resources, press releases, research, and multimedia content ... across the biomedical, biotechnology, medicine, surgery, and nursing, ... available with this free application. Updated ...
... Addicts ... ... economic times like these many students are postponing or quitting their educational pursuits for financial ... addict these challenges are not only real but exacerbated due to their personal fight. Today, ...
... while 87% of younger patients got it after surgery , ... are less likely than younger ones to receive potentially life-prolonging ... , The research indicates that those with advanced colon cancer ... likely to receive chemotherapy and more likely to receive less ...
... in the signature bracelet -- that they give to supporters when they make a minimum $15.00 donation -- they immediately took action.  The ... ... , ... ...
... to be associated with more appropriate follow-up and shorter ... an abnormal result on a mammogram, according to a ... of Internal Medicine , one of the JAMA/Archives journals. ... for Research on Inner City Health, St. Michael,s Hospital, ...
... News media, scientists and others interested in finance, entrepreneurship ... American Chemical Society (ACS) Small & Medium Business Webinar ... with subject matter experts and global thought leaders in ... of interest to scientific and engineering professionals. Each ...
Cached Medicine News:Health News:Academy's Community Initiative Offers Qualifying Former Addicts Free Vocational Training 2Health News:Older Colon Cancer Patients Less Likely to Get Chemo 2Health News:Older Colon Cancer Patients Less Likely to Get Chemo 3Health News:Older Colon Cancer Patients Less Likely to Get Chemo 4Health News:An Update on Mel's Bracelet 2
(Date:9/30/2014)... 2014 /CNW/ - Protecting the health and safety of Canadians is ... the appropriate powers and tools at its disposal to help ensure ... standards. To that end, Health Canada ... into Canada of all drug products from ... , Apotex Pharmachem India Pvt Ltd , ...
(Date:9/30/2014)... , Sept. 30, 2014 MiMedx Group, ... medicine company utilizing human amniotic tissue and patent-protected processes ... the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic ... Tom Koob , Ph.D., Chief Scientific Officer, will present ... Koob will present on Tuesday, October 7, 2014, at ...
(Date:9/30/2014)... 2014 Arbor Pharmaceuticals, LLC. - Product ... Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product Pipeline ... Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development focus. ... current therapeutic developmental pipeline of Arbor Pharmaceuticals, LLC.,s, ... assessment by drug target, mechanism of action (MoA), ...
Breaking Medicine Technology:Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2MiMedx to Present at the Stem Cell Meeting on the Mesa 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3
... RATON, Fla., Oct. 9 VitalRemedyMD, a physician-established ... to improve the quality of traditional healthcare. "We ... part of Fresenius, armamentarium in helping patients with ... of VitalRemedyMD. A state-of-the-art medical food, VitalProteinRx is ...
... Resources Inc. (PINK SHEETS: ASFX) is pleased to make available ... and December 31, 2008. These reports may be viewed in ... , American Scientific Resources, Inc., ... next-generation, health, medical, and safety products distributed primarily through nationwide ...
Cached Medicine Technology:Fresenius Medical Care, N.A. Has Selected VitalRemedyMD's VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients 2American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008 2
... spectrophotometer designed specifically to run 24 hours ... rugged hardware, proven optical performance and a ... traditional spectrophotometry to obtain results quickly, accurately ... up to eight, 1 cm Biocell cuvettes ...
The PerkinElmer LS 45 Luminescence spectrometer offers versatility, reliability and ease-of-use for routine analyses in an affordable package....
... a new generation Spectrophotometer for near ... nm to 1020 nm with built-in ... and printer. It features four digit ... transmittance, absorption and concentration with excellent ...
... UV/visible spectrophotometers provide ease-of-use and proven technology ... DU Series 800 high-performance spectrophotometers with microfocused ... as small as 5 l. The DU ... intended for use in quantitative and qualitative ...
Medicine Products: